Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye-Authors' reply

Affiliations

¹ Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, Netherlands. Electronic address: r.w.f.vanleeuwen@erasmusmc.nl.
² Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, Netherlands; Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, Netherlands.
³ Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, Netherlands.
⁴ Department of Clinical Pharmacy, Deventer Hospital, Deventer, Netherlands; Department of Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, Netherlands.

Comment

Roelof W F van Leeuwen et al. Lancet Oncol. 2014 Oct.

. 2014 Oct;15(11):e470-1.

doi: 10.1016/S1470-2045(14)70459-0.

¹ Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, Netherlands. Electronic address: r.w.f.vanleeuwen@erasmusmc.nl.
² Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, Netherlands; Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, Netherlands.
³ Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, Netherlands.
⁴ Department of Clinical Pharmacy, Deventer Hospital, Deventer, Netherlands; Department of Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, Netherlands.

No abstract available

Comment on

Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective.
van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. van Leeuwen RW, et al. Lancet Oncol. 2014 Jul;15(8):e315-26. doi: 10.1016/S1470-2045(13)70579-5. Lancet Oncol. 2014. PMID: 24988935 Review.